6-溴-1-甲基-1H-苯并[D]咪唑 | 53484-16-5

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 6-溴-1-甲基-1H-苯并[D]咪唑
• 中文别名: 6-溴-1-甲基苯并咪唑；6-溴-1-甲基-1H-苯并咪唑
• 英文名称: 6-bromo-1-methyl-1H-benzo[d]imidazole
• 英文别名: 6-bromo-1-methyl-benzimidazole；6-bromo-1-methylbenzimidazole
• CAS: 53484-16-5
• 化学式: C₈H₇BrN₂
• mdl: MFCD09027271
• 分子量: 211.061
• InChiKey: QDXJAGXUNYFXRG-UHFFFAOYSA-N

物化性质

• 沸点：
  317.2±34.0 °C(Predicted)
• 密度：
  1.60

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromo-1-methyl-1H-benzo[d]imidazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-1-methyl-1H-benzo[d]imidazole
CAS number: 53484-16-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H7BrN2
Molecular weight: 211.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴-1-甲基-1H-苯并[D]咪唑 在 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium hydroxide 、 2-二-叔丁膦基-2',4',6'-三异丙基联苯 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 3.5h， 生成 1-methyl-1H-benzo[d]imidazol-6-ol
  参考文献：
  名称：

  WO2021041237A5

  摘要：

  公开号：

  WO2021041237A5
• 作为产物：
  描述：

  5-溴-N-甲基-2-硝基苯胺 在 3-氨基丙基三乙氧基硅烷 、 氯化铵 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 反应 9.0h， 生成 6-溴-1-甲基-1H-苯并[D]咪唑
  参考文献：
  名称：

  Leucettinibs，一类 DYRK/CLK 激酶抑制剂，灵感源自海洋海绵天然产物 Leucetamine B

  摘要：

  双特异性酪氨酸磷酸化调节激酶 (DYRK) 和 cdc2 样激酶 (CLK) 最近因其在各种病理学中的重要参与而引起了人们的关注。我们在此描述了一系列源自亮氨酰胺和海洋天然产物亮氨酰胺 B 的 DYRK/CLK 抑制剂。合成了 45 种带有融合的 [6 + 5]-杂芳基亚甲基的N 2-官能化 2-氨基咪唑啉-4-酮。苯并噻唑-6-基亚甲基被选为 15 个不同杂芳基亚甲基中最有效的残基。合成并广泛表征了186 个带有苯并噻唑-6-基亚甲基的N 2-取代 2-氨基咪唑啉-4-酮，统称为 Leucettinib。鉴定出亚纳摩尔 IC 50 （DYRK1A 为 0.5-20 nM）抑制剂，并在 DYRK1A 中对一种 Leucettinib 进行建模，并与 CLK1 和较弱抑制的脱靶 CSNK2A1 共结晶。合成了 Leucettinib 的激酶失活异构体（DYRK1A 上 >3–10 μM），称为

  DOI：

  10.1021/acs.jmedchem.3c00884

文献信息

• Solvent-Controlled, Site-Selective <i>N</i>-Alkylation Reactions of Azolo-Fused Ring Heterocycles at N1-, N2-, and N3-Positions, Including Pyrazolo[3,4-<i>d</i>]pyrimidines, Purines, [1,2,3]Triazolo[4,5]pyridines, and Related Deaza-Compounds
  作者：Brett C. Bookser、Michael I. Weinhouse、Aaron C. Burns、Andrew N. Valiere、Lino J. Valdez、Pawel Stanczak、Jim Na、Arnold L. Rheingold、Curtis E. Moore、Brian Dyck

  DOI：10.1021/acs.joc.8b00540

  日期：2018.6.15

  coordinated to sodium indicated a potential role for the latter reinforcing the N2-selectivity. Limits of selectivity were tested with 26 heterocycles which revealed that N7 was a controlling element directing alkylations to favor N2 for pyrazolo- and N3 for imidazo- and triazolo-fused ring heterocycles when conducted in THF. Use of 1H-detected pulsed field gradient-stimulated echo (PFG-STE) NMR defined

  使用NaHMDS作为碱，在THF中用碘甲烷将4-甲氧基-1 H-吡唑并[3,4- d ]嘧啶（1b）烷基化，选择性地提供了N2-甲基产物4-甲氧基-2-甲基-2 H-吡唑并[3，相对于N1-甲基产物（2b），以8/1的比例存在4- d ]嘧啶（3b）。有趣的是，在DMSO中进行反应使选择性逆转，以提供4/1的N1 / N2甲基化产物比例。产品3b的晶体结构N1和N7与钠配位表明后者可能增强N2选择性。用26个杂环测试了选择性极限，结果表明，当在THF中进行反应时，N7是控制烷基化的控制元素，对于吡唑并环而言，该环对吡唑并环反应有利于N2，对咪唑和三唑并稠合的环杂环则有利于N3。使用1个H-检测脉冲场梯度受激回波（PFG-STE）NMR确定的离子反应性复合物的分子量。该数据和DFT电荷分布计算表明，紧密离子对（CIP）或紧密离子对（TIP）控制THF中的烷基化选择性，而溶剂分离的离子对（SIPs）是DMSO中的反应性物质。
• [EN] BENZIMIDAZOLE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET LEURS UTILISATIONS
  申请人：PELOTON THERAPEUTICS INC

  公开号：WO2015175845A1

  公开（公告）日：2015-11-19

  Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.

  公开了公式I的苯并咪唑衍生物，其调节ACSS2的活性，用于治疗。所公开的化合物的融合咪唑环在2位上连接有二芳基甲基或二芳基甲醇基团，并且这些化合物在苯并咪唑的5位或6位至少有另一个取代基。还公开了使用苯并咪唑化合物治疗疾病或疾病的方法，如癌症。
• [EN] PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS<br/>[FR] COMPOSÉS DE PYRAZOLE ET LEUR UTILISATION EN TANT QUE BLOQUEURS DES CANAUX CALCIQUES DE TYPE T
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2015186056A1

  公开（公告）日：2015-12-10

  The invention relates to compounds of formula (I) Formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.

  这项发明涉及式(I)的化合物。式(I)中X、Y、R1、R2、(R4)n和(R5)m的定义如描述中所述，并且涉及这些化合物的药用盐。这些化合物可用作钙T通道阻滞剂。
• [EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100695A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• [EN] GAMMA SECRETASE MODULATORS<br/>[FR] MODULATEURS DE LA GAMMA-SÉCRÉTASE
  申请人：AMGEN INC

  公开号：WO2009075874A1

  公开（公告）日：2009-06-18

  The present invention provides compounds that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了作为γ-分泌酶调节剂的化合物，因此可用于治疗可通过调节γ-分泌酶治疗的疾病，如阿尔茨海默病。还提供了含有此类化合物的药物组合物以及制备此类化合物的过程。